文献速递肿瘤 PET/CT骨显像与常规 SPECT

[18F]FDG PET/CT在常规检查阴性或可疑转移或局限复发的软组织或骨肉瘤患者初始分期与再分期中的应用:前瞻性多中心注册研究结果

[18F]FDG PET/CT in the Initial Staging and Restaging of Soft-Tissue or Bone Sarcoma in Patients with Negative or Equivocal Findings for Metastases or Limited Recurrence on Conventional Work-up: Results of a Prospective Multicenter Registry.
PubMed 文献 · J Nucl Med · 2023-07-06

该单臂前瞻性多中心注册研究纳入304例患者共320次[18F]FDG PET/CT检查,评估其在软组织或骨肉瘤初始分期与再分期中对临床管理和结局的影响。结果显示PET/CT常检出常规影像未见的转移灶,使约三分之一患者的治疗意图或治疗类型发生改变,且PET/CT示转移与更差生存相关。

要点

  • 初始分期中,常规检查无转移的105例中17例(16.2%)经PET/CT检出转移。
  • 再分期时123例中PET/CT检出局部复发37例(30.1%)、远处转移71例(57.7%)。
  • PET/CT示转移与初始分期无进展生存期缩短(P=0.04)及复发时总生存期缩短(P=0.002)相关。

核心结论

  • 在考虑根治性或挽救性治疗的肉瘤患者中,[18F]FDG PET/CT较常规影像常检出额外病灶,约三分之一患者的临床管理因此改变,PET/CT示转移与更差结局相关。

研究设计与样本

  • 单臂、前瞻性多中心注册研究,2018年11月至2021年10月纳入304例患者共320次[18F]FDG PET/CT检查。
  • 入选条件为初始分期2级及以上或无法分级的软组织或骨肉瘤、常规影像淋巴结或远处转移阴性或可疑且拟行根治性治疗,或既往治疗过的肉瘤疑似或确认局部复发或局限转移且考虑根治性或挽救性治疗的再分期。
  • 记录PET/CT所示局部复发或转移,将PET/CT后临床管理与PET/CT前计划管理比较,并将定量代谢肿瘤参数(SUVmax、代谢肿瘤体积、总病灶糖酵解)与171例患者的结局数据相关联。

主要发现

  • 初始分期中,常规检查无转移的105例中17例(16.2%)经PET/CT检出转移;常规检查可疑转移的92例中44例(47.8%)经PET/CT确认转移。
  • 再分期时,123例中PET/CT检出局部复发37例(30.1%)、远处转移71例(57.7%)。
  • 171例中记录治疗意图改变64例(37.4%)、治疗类型改变56例(32.8%)。
  • PET/CT示转移与初始分期无进展生存期缩短相关(P=0.04),与复发时总生存期缩短相关(P=0.002)。
  • 所有定量代谢肿瘤参数均与无进展生存期和总生存期相关。

临床怎么用

  • 在常规影像阴性或可疑、拟行根治性或挽救性治疗的软组织或骨肉瘤患者中,[18F]FDG PET/CT可检出额外病灶并影响临床管理。
  • PET/CT示转移与更差的生存结局相关,作者结论认为PET/CT所示转移与更差结局相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study was to determine the impact of [18F]FDG PET/CT on the initial staging, restaging, clinical management, and outcomes of patients with soft-tissue and bone sarcomas. Methods: This single-arm, prospective multicenter registry enrolled 304 patients with 320 [18F]FDG PET/CT scans (November 2018 to October 2021). Eligibility included the initial staging of a grade 2 or higher or ungradable soft-tissue or bone sarcoma, with negative or equivocal findings for nodal or distant metastases on conventional imaging before curative-intent therapy, or restaging of patients with a history of treated sarcoma with a suspicion or confirmation of local recurrence or limited metastatic disease who were being considered for curative-intent or salvage therapy. The presence of local recurrence or metastases on [18F]FDG PET/CT was recorded. Clinical management after [18F]FDG PET/CT compared with pre-[18F]FDG PET/CT planned management and quantitative metabolic tumor parameters (SUVmax, metabolic tumor volume, total lesion glycolysis) were correlated with the outcome data for 171 patients. Results: At the initial staging, [18F]FDG PET/CT detected metastases in 17 of 105 patients (16.2%) with no metastases on conventional work-up and confirmed metastases in 44 of 92 patients (47.8%) with equivocal findings for metastases. At the time of restaging, [18F]FDG PET/CT detected local recurrence in 37 of 123 patients (30.1%) and distant metastases in 71 of 123 patients (57.7%). Overall, the change in treatment intent and treatment type was recorded in 64 of 171 cases (37.4%) and 56 of 171 cases (32.8%), respectively. The presence of metastases on [18F]FDG PET/CT was associated with shorter progression-free survival at the initial staging (P = 0.04) and shorter overall survival at the time of recurrence (P = 0.002). All quantitative metabolic tumor parameters correlated with progression-free survival and overall survival. Conclusion: [18F]FDG PET/CT frequently detects additional sites of disease compared with conventional imaging in patients with sarcomas that were being considered for curative-intent or salvage therapy. This increased detection impacts the clinical management in a third of patients referred for initial staging or presumed limited recurrence after primary therapy. The presence of metastases on [18F]FDG PET/CT is associated with poorer outcomes.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Metser U, Kulanthaivelu R, Salawu A, et al. [18F]FDG PET/CT in the Initial Staging and Restaging of Soft-Tissue or Bone Sarcoma in Patients with Negative or Equivocal Findings for Metastases or Limited Recurrence on Conventional Work-up: Results of a Prospective Multicenter Registry. J Nucl Med. 2023. PMID: 37414444. doi:10.2967/jnumed.122.265278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。